Literature DB >> 1322794

Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.

S Garbisa1, G Scagliotti, L Masiero, C Di Francesco, C Caenazzo, M Onisto, M Micela, W G Stetler-Stevenson, L A Liotta.   

Abstract

Cancer cells elaborate metalloproteinases which may play a role in invasion and metastasis. The serum level of the M(r) 72,000 type IV collagenase (MMP-2) was measured in 87 lung cancer patients. Stage IV cancer levels were significantly elevated (P less than 0.0001) compared to normal sera. A significant difference (P less than 0.01) was found between enzyme levels in the presence versus the absence of distant metastasis. For 29 patients treated with combination chemotherapy, a positive relationship was noted between response failure and elevated enzyme levels. Serum metalloproteinase levels may provide information relevant to prognosis as well as treatment decisions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322794

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia.

Authors:  F Kumaki; K Matsui; T Kawai; Y Ozeki; Z X Yu; V J Ferrans; W D Travis
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity.

Authors:  A Ladányi; J O Nagy; A Jeney; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

4.  Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases.

Authors:  A Matsuzaki; A Janowska-Wieczorek
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 5.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

Review 7.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

8.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Authors:  J E Park; G A Keller; N Ferrara
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

10.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.